Recently, a systematic review with meta-analysis presented at the ESMO Meeting [70] explored this correlation and, despite the small number of included studies, showed that VEGF-A plasma levels seemed to predict benefit with bevacizumab in early and advanced breast cancer. Here, VEGFA is linked to breast cancer.